800 Research Parkway
58 articles with Cytovance Biologics
Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization of mammalian and microbial biologics, announces the appointment of Mr. Bin Zhang as Chief Executive Officer.
GT Biopharma, Inc. (OTCQB:GTBP) announced today that it had entered into a partnership agreement with Cytovance Biologics, a USA-based contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink").
Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization, announces the addition of Mass Spectrometry to its Analytical Development suite of services.
Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization, announces the promotion of Dr. John Mott to Vice President of Development.
Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization, announces Yuk Chun Chiu as Vice President of Manufacturing Operations.
Cytovance Biologics and Akshaya Bio Announce Collaboration Agreement of Therapeutics for Treatment of Coronavirus and Hepatitis B Virus Infections
Cytovance® Biologics announced that it has entered into a collaboration agreement with Akshaya Bio, Inc., a Canadian development stage biotechnology company to provide rapid access to clinical materials using Akshaya’s proprietary Chimigen® Platform Technology for vaccine development for COVID-19 and HBV..
Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization, announces the appointment of Dr. Jesse McCool to Chief Executive Officer.
Cytovance® Biologics Introduces an Integrated Single-use Platform for Plasmid DNA (pDNA) Manufacture
One grade is available (R&D-grade) in lot sizes from 1g to 5g.
Cytovance Biologics to Participate in RAFT Scientific Discussion on Commercialization of Fermentation Processes
Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced the company will participate in the upcoming Recent Advances in Fermentation Technology Conference to be held October 29 - November 1, 2017 at the Hyatt Coconut Point, Bonita Springs, Florida.
Horizon Discovery enters into license agreement with Cytovance Biologics for HD-BIOP3 Suspension adapted GS null CHO K1 cells
Cytovance® Biologics, Inc. signed a non-exclusive license with Horizon Discovery for the use of their HD-BIOP3 Suspension adapted GS null CHO K1 cells.
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
Edwin Miranda will be leading the full breadth of Cytovance’s Quality function.
Cytovance Biologics Announces Bexion Pharmaceuticals Has Chosen Cytovance to Manufacture the Protein Component and Active Ingredient Of Bexion’s First Clinical Compound, BXQ-350
An ongoing supply of this protein will support Bexion’s continued drug development efforts, including planned Phase II clinical trials.
Cytovance Biologics Inc.' Jesse McCool, Ph.D., To Present At 2015 BioInnovation Summit In London, UK